 | |
| Names | |
|---|---|
| IUPAC name 3,3′-Neoligna-8,8′-diene-4,4′-diol | |
| Systematic IUPAC name 5,5′-Di(prop-2-en-1-yl)[1,1′-biphenyl]-2,2′-diol | |
| Other names Dehydrodichavicol 5,5'-Diallyl-2,2'-dihydroxybiphenyl 5,5'-Diallyl-2,2'-biphenyldiol | |
| Identifiers | |
| |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider |
|
| ECHA InfoCard | 100.127.908 |
| KEGG |
|
| UNII | |
| |
| |
| Properties | |
| C18H18O2 | |
| Molar mass | 266.340 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Magnolol is anorganic compound that is classified aslignan. It is abioactive compoundfound in the bark of the Houpu magnolia (Magnolia officinalis) and inM. grandiflora.[2]
Magnolol is a compound that acts onGABA_A receptors and functions as an allosteric modulator. It hasantifungal properties and demonstrates anti-periodontal disease effects in animal models. In cell cultures, magnolol stimulatesosteoblasts and inhibitsosteoclasts, indicating potential for anti-osteoporosis treatment. It also binds in a dimeric form toPPARγ, acting as an agonist of this nuclear receptor. Additionally, magnolol may interact withcannabinoid receptors, acting as a partial agonist of CB2 receptors with lower affinity for CB1 receptors.
It is known to act on theGABAA receptors in rat cellsin vitro[3] as well as having antifungal properties.[4] Magnolol has a number of osteoblast-stimulating and osteoclast-inhibiting activities in cell culture and has been suggested as a candidate for screening for anti-osteoporosis activity.[5] It has anti-periodontal disease activity in a rat model.[6] Structural analogues have been studied and found to be strong allosteric modulators ofGABAA.[7]
Magnolol is also binding in dimeric mode toPPARγ, acting as an agonist of this nuclear receptor.[8]
Magnolol may interact withcannabinoid receptors, acting as a partial agonist ofCB2 receptors, with lower affinity for theCB1 receptor.[9]
